Osteogenesis Imperfecta Clinical Trial
Official title:
A Natural History of the Collagen-Related Disorder Osteogenesis Imperfecta and the Genotype-Phenotype Correlation
Background: Osteogenesis Imperfecta (OI) is a connective tissue disorder. OI affects many aspects of a person s health and growth. It can cause frequent fractures, short stature, and bowing of the long bones. There is no known cure for OI so researchers want to learn more about it. Objectives: To obtain a natural history of the course of OI. To find changes in genes that affect the disease. Eligibility: People from birth to age 12 years with certain types of OI People who previously had childhood data collected in certain other protocols Design: Participants will stay in the clinic for a few days each visit. Visits will be about every 3-4 months to age 5 then about every 6-12 months. Visits may include: Medical history Physical exam Hearing test Dental exam Blood, urine, and heart tests Breathing measured while wearing a clear plastic hood for about 30 minutes Tests of motion, strength, and motor skills X-rays of the left hand, chest, legs, and spine Bone density scan. Participants will lie on a flat table while a very small dose of x-rays is passed through the body. Computed tomography and magnetic resonance imaging scans. Participants will lie on an exam table that moves in and out a scanner. Breathing tests using stickers on the chest, a light probe on a finger or foot, and a face mask Ultrasound of the kidneys, ureters, and bladder Questionnaires A small section of skin removed from the arm or thigh For some tests, participants may take medicine to make them sleepy. Participants may give separate consent for photos to be taken.
study Description: This is a longitudinal study of the natural history of the collagen-related disorder osteogenesis imperfecta (OI), that includes enrolling new patients under the age of 12 years, along with an extended data collection from adult patients on whom previous childhood data was collected at the NIH. Objectives: Primary Objectives: 1) Identify and monitor longitudinal functional outcomes of individuals with collagen and collagen-related disorders, with focuses on identifying underlying contributing factors and comorbidities for scoliosis; gaining insight into occurrence and progression of cardiac valvular abnormalities; pathogenesis of primary lung parenchymal defects; and establish novel data relating to metabolism in OI and its relationship to obesity. 2) Correlate genotypic and phenotypic expression. 3) Identify genetic factors that modify the severity of clinical expression Secondary Objectives: Adapt and develop standard of care management guidelines for individuals with collagen and collagen-related disorders. Endpoints: Primary Endpoints: 1) Clinical course, underlying pathogenesis, and comorbidities in the assessed systems in individuals with OI including for each focus: scoliosis progression across age, scoliosis progression relating to predictive factor, and scoliosis progression relating to mutation spectrum; time to development of valvular abnormality; development of pulmonary tissue abnormalities, presence/absence of pulmonary tissue abnormality, and time to development of pulmonary tissue abnormality; time to development of metabolic abnormality. 2) Correlation of phenotype relating to genotype. 3) Causes of morbidities in individuals with OI. Secondary endpoints: Tolerability and feasibility of each measure of the clinical battery of assessments based on clinical observation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Recruiting |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 |